Nuvation Bio Inc

NYSE:NUVBUnited States

Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.

Contact Information

Headquarters

357 Tehama Street, Floor 3SAN FRANCISCO, CA, United States 94103

Phone

415-754-3517

Fax

302-636-5454

Executives

Independent Chair of the Board

Daniel Welch

President, Chief Executive Officer, Founder, Director

David Hung

Principal Financial and Accounting Officer, Vice President - Finance

Moses Makunje

Chief Executive Officer of AnHeart Therapeutics and Director

Junyuan Wang

Chief People Officer

Stacy Markel